LENZ Therapeutics, Inc. (LENZ)
3.15
0.00 (0.00%)
USD |
NASDAQ |
Oct 27, 16:00
3.21
+0.06
(+1.90%)
After-Hours: 20:00
LENZ Therapeutics Enterprise Value : -120.47M for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | -120.47M |
| October 26, 2026 | -120.63M |
| October 23, 2026 | -120.16M |
| October 22, 2026 | -117.33M |
| October 21, 2026 | -118.27M |
| October 20, 2026 | -119.21M |
| October 19, 2026 | -115.76M |
| October 16, 2026 | -116.70M |
| October 15, 2026 | -107.28M |
| October 14, 2026 | -111.67M |
| October 13, 2026 | -112.62M |
| October 12, 2026 | -106.02M |
| October 09, 2026 | -104.92M |
| October 08, 2026 | -108.53M |
| October 07, 2026 | -105.70M |
| October 06, 2026 | -100.36M |
| October 05, 2026 | -106.65M |
| October 02, 2026 | -106.96M |
| October 01, 2026 | -100.36M |
| September 30, 2026 | -98.79M |
| September 29, 2026 | -98.16M |
| September 28, 2026 | -95.02M |
| September 25, 2026 | -96.44M |
| September 24, 2026 | -102.56M |
| September 23, 2026 | -101.31M |
| Date | Value |
|---|---|
| September 22, 2026 | -89.68M |
| September 21, 2026 | -91.25M |
| September 18, 2026 | -91.57M |
| September 17, 2026 | -89.68M |
| September 16, 2026 | -89.37M |
| September 15, 2026 | -86.54M |
| September 14, 2026 | -79.00M |
| September 11, 2026 | -77.43M |
| September 10, 2026 | -71.15M |
| September 09, 2026 | -65.18M |
| September 08, 2026 | -51.98M |
| September 04, 2026 | -32.19M |
| September 03, 2026 | -36.27M |
| September 02, 2026 | -37.22M |
| September 01, 2026 | -55.12M |
| August 31, 2026 | -55.75M |
| August 28, 2026 | -58.89M |
| August 27, 2026 | -68.32M |
| August 26, 2026 | -69.26M |
| August 25, 2026 | -72.72M |
| August 24, 2026 | -75.23M |
| August 21, 2026 | -72.40M |
| August 20, 2026 | -73.03M |
| August 19, 2026 | -64.86M |
| August 18, 2026 | -69.58M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Impact BioMedical, Inc. | 33.57M |
| Enveric Biosciences, Inc. | -2.707M |
| Liquidia Corp. | 3.947B |
| Aquestive Therapeutics, Inc. | 561.43M |
| ANI Pharmaceuticals, Inc. | 1.870B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.92M |
| Revenue (Quarterly) | 5.486M |
| Total Expenses (Quarterly) | 37.40M |
| EPS Diluted (Quarterly) | -1.017 |
| Gross Profit Margin (Quarterly) | 94.90% |
| Profit Margin (Quarterly) | -581.8% |
| Earnings Yield | -129.6% |
| Normalized Earnings Yield | -129.56 |